ClinicalTrials.gg
CompletedNCT00571649MAGELLANUpdated Sep 15, 2016Results posted

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Enoxaparin in Venous Thromboembolism, sponsored by Bayer. Completed at 676 sites in 53 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,101
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.

Enrollment
2nd of 61
8,101 · median 272
Started
2007
with 1 other
Phase 3
26 of 61
5 open now
Registered
10th of 61
by date
Lead sponsor
15 of 61
Bayer

Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 2nd largest by enrollment, is one of 2 that started in 2007, is one of 26 in phase 3, and was the 10th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing rivaroxaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.

Read the detailed description

The treatment period was followed by a follow-up period starting the day after the last intake of study medication, regardless of the actual duration of study drug administration and ended on Day 90 (+ 7 days). Participants who did not complete the treatment period also entered the follow-up period. It was also possible that participants did not enter the follow-up period, e.g. due to withdrawal of consent or termination of study participation.

Within the US 'Johnson \& Johnson Pharmaceutical Research \& Development, L.L.C.' is sponsor.

03

Conditions studied

  • Venous Thromboembolism

Keywords

  • Acute medical illnesses with increased risk for VTE.
  • Deep vein thrombosis (DVT)
  • Pulmonary embolism (PE),
  • Venous Thromboembolic disease (VTE),
  • Medical illness
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 40 years or more
  • Patients at risk of venous thromboembolic events being hospitalized for acute medical conditions as follows:

    • Heart failure, (NYHA) class III or IV
    • Active cancer
    • Acute ischemic stroke
    • Acute infectious and inflammatory diseases, including acute rheumatic diseases
    • Acute respiratory insufficiency
    • Additional risk factor for VTE, including reduced mobility

Exclusion criteria

Exclusion Criteria:

  • Conditions that contraindicate the use of antithrombotic therapy with the Low Molecular-Weight Heparin (LMWH) enoxaparin
  • Conditions that may increase the risk of bleeding, including intracranial hemorrhage
  • Required drugs or procedures which may interfere with the study treatment
  • Concomitant conditions or diseases which may increase the risk of study subjects or interfere with the study outcome
  • General conditions in which subjects are not suitable to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8,101 participants (actual)

Study arms

  • Experimental
    Rivaroxaban (Xarelto, BAY59-7939)

    Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days

    Drug: Rivaroxaban (Xarelto, BAY59-7939) · Drug: Enoxaparin placebo

  • Active comparator
    Enoxaparin

    Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days

    Drug: Enoxaparin · Drug: Rivaroxaban placebo

Interventions

  • Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days

  • Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days

  • DrugRivaroxaban placebo

    Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days

  • DrugEnoxaparin placebo

    Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days

    A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

    Time frame: Up to Day 35 + 6 days

  2. Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

    A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

    Time frame: Up to Day 10 + 5 days

Secondary outcomes

  1. Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days

    A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related).

    Time frame: Up to Day 35 + 6 days

  2. Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population

    A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

    Time frame: Up to Day 10 + 5 days

  3. Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days

    A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related).

    Time frame: Up to Day 10 + 5 days

  4. Percentage of Participants With Symptomatic VTE, Including and Excluding VTE-related Death up to Days 10, 35, and 90

    Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90

    Time frame: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days

  5. Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days

    Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events.

    Time frame: Up to Day 35 + 6 days

  6. Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days

    Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events

    Time frame: Up to Day 10 + 5 days

  7. Percentage of Participants With Major Vascular Events up to Days 10, 35, and 90

    Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category.

    Time frame: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days

  8. Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 35 + 6 Days

    The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

    Time frame: Up to Day 35 + 6 days

  9. Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

    The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

    Time frame: Up to Day 10 + 5 days

  10. Percentage of Participants With All-cause Mortality up to Day 90 + 7 Days

    All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths.

    Time frame: Up to Day 90 + 7 days

  11. Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)

    Major bleeding events were defined as events leading to \>=2 g/dL fall in hemoglobin; or transfusion of \>= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding

    Time frame: Up to Day 35 + 6 days

  12. Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)

    Major bleeding events were defined as events leading to \>=2 g/dL fall in hemoglobin or transfusion of \>=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding.

    Time frame: Up to Day 10 + 5 days

07

Results

Posted Jun 27, 2012
Limitations and caveats
A heterogeneous population (with different acute medical illnesses and severity of illness) was included in the trial. VTE risk in acute medical illnesses is moderate \[with no thromboprophylaxis\] .

Participant flow

First patient first visit date: 04 DEC 2007; last patient last visit date 24 NOV 2010. Primary completion date: 12 AUG 2010. Participants were aged ≥40 years, hospitalized for an acute medical illness, and at risk of Venous Thromboembolism (VTE) (with heart failure, cancer, ischemic stroke, infection or inflammation, or respiratory insufficiency)

Treatment Period
Participant flow — Treatment Period
MilestoneRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Started40504051
Participants received treatment39974001
Day 1034543499
Day 3530333115
Completed29583047
Not completed10921004
Withdrew: Adverse event438385
Withdrew: Clinical endpoint reached5056
Withdrew: Withdrawal by subject285255
Withdrew: Death7659
Withdrew: Physician decision89
Withdrew: Lost to follow-up4341
Withdrew: Non-compliant with study medication8889
Withdrew: Patient convenience1113
Withdrew: Protocol violation9092
Withdrew: Technical problems35
Follow-up Period
Participant flow — Follow-up Period
MilestoneRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Started35833635
Completed30383107
Not completed545528
Withdrew: Adverse event4640
Withdrew: Clinical endpoint reached52
Withdrew: Withdrawal by subject119115
Withdrew: Death132133
Withdrew: Physician decision713
Withdrew: Lost to follow-up9592
Withdrew: Patient convenience136121
Withdrew: Protocol violation512

Outcome measures

PrimaryPercentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

Time frame:
Up to Day 35 + 6 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days4.45.7
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin · Cochran-Mantel-Haenszel · p = 0.0211 (Hochberg procedure: A 2-sided p-value of less than 0.05 would be considered significant, if the 1-sided p-value of the other primary efficacy outcome measure was less than 0.025, elsewise a p-value of less than 0.025 would be considered significant.) · Risk ratio (rr): 0.771 · 95% CI 0.618 to 0.962Weighted relative risks were calculated using asymptotic methods, with weights based upon sample sizes per strata (geographic region).
PrimaryPercentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

Time frame:
Up to Day 10 + 5 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days2.72.7
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin · Cochran-Mantel-Haenszel · p = 0.0025 (Hochberg procedure: A 1-sided p-value of less than 0.025 would be considered significant, if the 2-sided p-value of the other primary efficacy outcome measure was less than 0.05, elsewise a p-value of less than 0.0125 would be considered significant.) · Risk ratio (rr): 0.968 · 95% CI 0.713 to 1.314Weighted relative risks were calculated using asymptotic methods, with weights based upon sample sizes per strata (geographic region).
SecondaryPercentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related).

Time frame:
Up to Day 35 + 6 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days8.69.2
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin · Cochran-Mantel-Haenszel · p = 0.3758 (Test hierarchy: A p-value of less than 0.05 would be considered significant, if the tests for the two primary efficacy outcome measures were significant.) · Risk ratio (rr): 0.931 · 95% CI 0.795 to 1.091Weighted relative risks were calculated using asymptotic methods, with weights based upon sample sizes per strata (geographic region).
SecondaryPercentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

Time frame:
Up to Day 10 + 5 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population3.03.1
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin · Cochran-Mantel-Haenszel · p = 0.9473 (Test hierarchy: A p-value of less than 0.05 would be considered significant, if the tests for the 2 primary efficacy outcomes and for "Composite endpoint of VTE (any DVT, non fatal PE) and all-cause mortality up to Day 35 + 6 days" were significant.) · Risk ratio (rr): 0.991 · 95% CI 0.753 to 1.304Weighted relative risks were calculated using asymptotic methods, with weights based upon sample sizes per strata (geographic region).
SecondaryPercentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related).

Time frame:
Up to Day 10 + 5 days
Reported as:
Number · Percentage of participants
Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days4.84.5
SecondaryPercentage of Participants With Symptomatic VTE, Including and Excluding VTE-related Death up to Days 10, 35, and 90

Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90

Time frame:
At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Symptomatic VTE, Including and Excluding VTE-related Death up to Days 10, 35, and 90
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
symptomatic VTE (incl. VTE-related death)-Day 100.70.6
symptomatic VTE (non fatal)-Day 100.50.3
symptomatic VTE (incl. VTE-related death)-Day 351.01.4
symptomatic VTE (non fatal)-Day 350.60.7
symptomatic VTE (incl. VTE-related death)-Day 901.71.9
symptomatic VTE (non fatal)-Day 900.70.9
SecondaryPercentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days

Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events.

Time frame:
Up to Day 35 + 6 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days9.47.8
SecondaryPercentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days

Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events

Time frame:
Up to Day 10 + 5 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days4.53.9
SecondaryPercentage of Participants With Major Vascular Events up to Days 10, 35, and 90

Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category.

Time frame:
At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Vascular Events up to Days 10, 35, and 90
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Any event-Day 101.01.0
Ischemic stroke-Day 100.30.3
Acute MI-Day 100.50.4
Death (cardiovascular)-Day 100.40.4
Any event-Day 351.81.6
Ischemic stroke-Day 350.50.5
Acute MI-Day 350.60.5
Death (cardiovascular)-Day 350.90.8
Any event-Day 902.82.8
Ischemic stroke-Day 900.81.1
Acute MI-Day 900.90.7
Death (cardiovascular)-Day 901.41.4
SecondaryPercentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 35 + 6 Days

The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

Time frame:
Up to Day 35 + 6 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 35 + 6 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Symptomatic non-fatal PE0.30.5
Symptomatic DVT in lower extremity0.40.5
Asymptomatic proximal DVT in lower extremity3.54.4
VTE related death0.61.0
SecondaryPercentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.

Time frame:
Up to Day 10 + 5 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Symptomatic non-fatal PE0.20.1
Symptomatic DVT in lower extremity0.20.2
Asymptomatic proximal DVT in lower extremity2.42.4
VTE related death0.10.2
SecondaryPercentage of Participants With All-cause Mortality up to Day 90 + 7 Days

All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths.

Time frame:
Up to Day 90 + 7 days
Reported as:
Number · Percentage of participants
Percentage of Participants With All-cause Mortality up to Day 90 + 7 Days
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Any event6.76.2
Death (cardiovascular)1.41.4
Death (other)4.33.7
VTE related death1.01.1
SecondaryPercentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)

Major bleeding events were defined as events leading to \>=2 g/dL fall in hemoglobin; or transfusion of \>= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding

Time frame:
Up to Day 35 + 6 days
Reported as:
Number · Percentage of participants
Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)4.11.7
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin · Cochran-Mantel-Haenszel · p = <0.0001 (2-sided p-value. No adjustment for multiple testing.) · Risk ratio (rr): 2.455 · 95% CI 1.854 to 3.251Weighted relative risks were calculated using asymptotic methods, with weights based upon sample sizes per strata (geographic region).
SecondaryPercentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)

Major bleeding events were defined as events leading to \>=2 g/dL fall in hemoglobin or transfusion of \>=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding.

Time frame:
Up to Day 10 + 5 days
Reported as:
Number · Percentage of participants
Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)2.81.2
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin · Cochran-Mantel-Haenszel · p = <0.0001 (2-sided p-value. No adjustment for multiple testing.) · Risk ratio (rr): 2.272 · 95% CI 1.628 to 3.171

Adverse events

Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban (Xarelto, BAY59-7939)—1,034/3,997 (25.9%)2,297/3,997 (57.5%)
Enoxaparin—976/4,001 (24.4%)2,291/4,001 (57.3%)
Most frequent serious events
Showing 10 of 756
Most frequent serious events
EventRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders109/3997104/4001
Cardiac failureCardiac disorders76/399776/4001
PneumoniaInfections and infestations74/399776/4001
Respiratory failureRespiratory, thoracic and mediastinal disorders56/399740/4001
Ischaemic strokeNervous system disorders30/399739/4001
Acute respiratory failureRespiratory, thoracic and mediastinal disorders35/399712/4001
Cardiac failure congestiveCardiac disorders31/399731/4001
Renal failure acuteRenal and urinary disorders31/399716/4001
Acute myocardial infarctionCardiac disorders30/399728/4001
SepsisInfections and infestations29/399714/4001
Most frequent other events
Showing 10 of 98
Most frequent other events
EventRivaroxaban (Xarelto, BAY59-7939)Enoxaparin
ConstipationGastrointestinal disorders362/3997346/4001
DiarrhoeaGastrointestinal disorders214/3997230/4001
NauseaGastrointestinal disorders207/3997226/4001
HeadacheNervous system disorders205/3997185/4001
HypokalaemiaMetabolism and nutrition disorders191/3997184/4001
InsomniaPsychiatric disorders172/3997185/4001
VomitingGastrointestinal disorders170/3997149/4001
HypertensionVascular disorders154/3997156/4001
Urinary tract infectionInfections and infestations138/3997142/4001
Oedema peripheralGeneral disorders132/3997115/4001

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rivaroxaban (Xarelto, BAY59-7939)EnoxaparinTotal
Mean69.2 ± 11.969.2 ± 11.769.2 ± 11.8
Age, Customized
Age, Customized(participants)Rivaroxaban (Xarelto, BAY59-7939)EnoxaparinTotal
< 65 years132313632686
65 to < 75 years114410902234
>= 75 years153015483078
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (Xarelto, BAY59-7939)EnoxaparinTotal
Female177418983672
Male222321034326
Race
Race(participants)Rivaroxaban (Xarelto, BAY59-7939)EnoxaparinTotal
White274927445493
Black8992181
Asian7937941587
Native American121224
Hispanic6970139
Uncodable106112218
Unknown101
Missing178177355
Reason for hospitalization
Reason for hospitalization(participants)Rivaroxaban (Xarelto, BAY59-7939)EnoxaparinTotal
Heart failure (NYHA Class III or NYHA Class IV)129213012593
Active cancer294290584
Acute ischemic stroke6916921383
Acute Infectious and Inflammatory Diseases190418763780
Acute infectious disease182618013627
Acute inflammatory or rheumatic disease150149299
Acute respiratory insufficiency108511512236
08

Study locations

676 sites
  • Birmingham, Alabama 35209, United States
  • Birmingham, Alabama 35235, United States
  • Dothan, Alabama 36301, United States
  • Office of Dr. John Simmons, MD
    Geneva, Alabama 36340, United States
  • Mobile, Alabama 36608, United States
  • Montgomery, Alabama 36111, United States
  • Tuscaloosa, Alabama 35401, United States
  • Tuscaloosa, Alabama 35406, United States
  • Little Rock, Arkansas 72205, United States
  • Chula Vista, California 91911, United States
  • Duarte, California 91010, United States
  • Encinitas, California 92024, United States
  • Fountain Valley, California 92708, United States
  • Fullerton, California 92835, United States
  • Glendale, California 91206, United States
  • Oceanside, California 92056, United States
  • Pasadena, California 91105, United States
  • Redlands, California 92373, United States
  • Sacramento, California 95817, United States
  • San Diego, California 92120, United States
  • Santa Barbara, California 93102, United States
  • Torrance, California 90502-2004, United States
  • Denver, Colorado 80204, United States
  • Pueblo, Colorado 81003, United States
  • Wheat Ridge, Colorado 80033-6017, United States
  • Farmington, Connecticut 06030, United States
  • Newark, Delaware 19718, United States
  • Washington, District of Columbia 20037, United States
  • Aventura, Florida 33180, United States
  • Boyton Beach, Florida 33472, United States
  • Clearwater, Florida 33756, United States
  • Delray Beach, Florida 33445, United States
  • Ft. Lauderdale, Florida 33334, United States
  • Hollywood, Florida 33021, United States
  • Jupiter, Florida 33458, United States
  • Miami Springs, Florida 33166, United States
  • Miami, Florida 33136, United States
  • Miami, Florida 33173-3259, United States
  • Pembroke Pines, Florida 33024, United States
  • Port Charlotte, Florida 33952, United States
  • Sarasota, Florida 34232, United States
  • Vero Beach, Florida 32960, United States
  • Atlanta, Georgia 30342, United States
  • Decatur, Georgia 30030, United States
  • Fort Gordon, Georgia 30905, United States
  • Savannah, Georgia 31405, United States
  • Idaho Falls, Idaho 83404, United States
  • Chicago, Illinois 60611, United States
  • Springfield, Illinois 62702, United States
  • Anderson, Indiana 46011, United States
  • Noblesville, Indiana 46060, United States
  • Des Moines, Iowa 50314-2611, United States
  • Olathe, Kansas 66061, United States
  • Lafayette, Louisiana 70503, United States
  • New Orleans, Louisiana 70121, United States
  • Shreveport, Louisiana 71130-4228, United States
  • Biddeford, Maine 04005, United States
  • Rockport, Maine 04856, United States
  • Baltimore, Maryland 21215, United States
  • Baltimore, Maryland 21237, United States
  • Framingham, Massachusetts 01702, United States
  • Ann Arbor, Michigan 48106, United States
  • Detroit, Michigan 48201, United States
  • Detroit, Michigan 48202, United States
  • Grand Rapids, Michigan 49525, United States
  • Lansing, Michigan 48910, United States
  • Petoskey, Michigan 49770-2297, United States
  • Pontiac, Michigan 48341, United States
  • St. Clair Shores, Michigan 48081, United States
  • Minneapolis, Minnesota 55417, United States
  • Kansas City, Missouri 64128, United States
  • St. Louis, Missouri 63110, United States
  • St. Louis, Missouri 63141, United States
  • Anaconda, Montana 59711-2718, United States
  • Great Falls, Montana 59405, United States
  • Omaha, Nebraska 68131, United States
  • Hackensack, New Jersey 07601-1991, United States
  • New Brunswick, New Jersey 08901, United States
  • Somerville, New Jersey 08876-2598, United States
  • Summit, New Jersey 07901, United States
  • Teaneck, New Jersey 07666, United States
  • Brooklyn, New York 11215, United States
  • Buffalo, New York 14215-3021, United States
  • Jamaica, New York 11418, United States
  • New Hyde Park, New York 11040-1496, United States
  • New York, New York 10011, United States
  • New York, New York 10065, United States
  • Stony Brook, New York 11794, United States
  • Valhalla, New York 10595, United States
  • Durham, North Carolina 27710, United States
  • Elizabeth City, North Carolina 27909, United States
  • Greensboro, North Carolina 27403, United States
  • Fargo, North Dakota 58122, United States
  • Canton, Ohio 44718, United States
  • Columbus, Ohio 43215, United States
  • Maumee, Ohio 43537-1899, United States
  • Toledo, Ohio 43606, United States
  • Bethlehem, Pennsylvania 18015, United States
  • Camp Hill, Pennsylvania 17011, United States
  • Danville, Pennsylvania 17822, United States

Showing the first 100 of 676 sites across 53 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos A, Tapson V. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011 May;31(4):407-16. doi: 10.1007/s11239-011-0549-x. PubMed 21359646 ↗
  • Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096. PubMed 23388003 ↗
  • Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost. 2012 Oct;10(10):2053-60. doi: 10.1111/j.1538-7836.2012.04874.x. PubMed 22863355 ↗
  • Mebazaa A, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, Merli G, Schellong SW, Spyropoulos AC, Tapson VF, De Sanctis Y, Cohen AT. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation. 2014 Jul 29;130(5):410-8. doi: 10.1161/CIRCULATIONAHA.113.003126. Epub 2014 Jun 26. PubMed 24970782 ↗
  • Cohen AT, Spiro TE, Spyropoulos AC, Desanctis YH, Homering M, Buller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Tapson VF, Burton P; MAGELLAN Study Group. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost. 2014 Apr;12(4):479-87. doi: 10.1111/jth.12515. PubMed 24460645 ↗
  • Spyropoulos AC, Raskob GE, Cohen AT, Ageno W, Weitz JI, Spiro TE, Lu W, Lipardi C, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Sugarmann C, Barnathan ES. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 May 10;145(19):1471-1479. doi: 10.1161/CIRCULATIONAHA.121.057847. Epub 2022 Apr 7. PubMed 35389229 ↗
  • Raskob GE, Spyropoulos AC, Spiro TE, Lu W, Yuan Z, Levitan B, Suh E, Barnathan ES. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 Nov 16;10(22):e021579. doi: 10.1161/JAHA.121.021579. Epub 2021 Nov 10. PubMed 34755519 ↗
  • Raskob GE, Spyropoulos AC, Cohen AT, Weitz JI, Ageno W, De Sanctis Y, Lu W, Xu J, Albanese J, Sugarmann C, Weber T, Lipardi C, Spiro TE, Barnathan ES. Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. J Am Heart Assoc. 2021 Feb;10(5):e019459. doi: 10.1161/JAHA.120.019459. Epub 2021 Feb 15. PubMed 33586478 ↗
  • Jamil A, Jamil U, Singh K, Khan F, Chi G. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups. Crit Pathw Cardiol. 2021 Mar 1;20(1):16-24. doi: 10.1097/HPC.0000000000000232. PubMed 32657973 ↗
  • Weitz JI, Raskob GE, Spyropoulos AC, Spiro TE, De Sanctis Y, Xu J, Lu W, Suh E, Argenti D, Yang H, Albanese J, Lipardi C, Barnathan ES. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar;120(3):515-524. doi: 10.1055/s-0039-1701009. Epub 2020 Jan 23. PubMed 31975354 ↗
  • Chi G, Goldhaber SZ, Kittelson JM, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, Gibson CM. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017 Oct;15(10):1913-1922. doi: 10.1111/jth.13783. Epub 2017 Sep 4. PubMed 28762617 ↗
  • Marszalek J, Mehrsefat S, Chi G. The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis. Expert Rev Hematol. 2017 Aug;10(8):679-684. doi: 10.1080/17474086.2017.1343662. Epub 2017 Jun 21. PubMed 28617144 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Aug 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2007
First posted
Dec 12, 2007
Start
Dec 2007
Primary completionActual
Aug 2010
CompletionActual
Nov 2010
Results first posted
Jun 27, 2012
Last update
Sep 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00571649
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 12, 2007
Start date
Dec 2007
Primary completion
Aug 2010
Completion
Nov 2010
Results posted
Jun 27, 2012
Last update
Sep 15, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion